227 related articles for article (PubMed ID: 31577775)
1. Efficacy of treatment regimens for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
Chen QF; Wu PH; Huang T; Shen LJ; Huang ZL; Li W
Medicine (Baltimore); 2019 Oct; 98(40):e17460. PubMed ID: 31577775
[TBL] [Abstract][Full Text] [Related]
2. Network meta-analysis of treatment regimens for inoperable advanced hepatocellular carcinoma with portal vein invasion.
Li MF; Leung HW; Chan AL; Wang SY
Ther Clin Risk Manag; 2018; 14():1157-1168. PubMed ID: 30013351
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials.
Zeng J; Lv L; Mei ZC
Clin Res Hepatol Gastroenterol; 2016 Dec; 40(6):688-697. PubMed ID: 27339594
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sorafenib combined with TACE in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
Li D; Pang Y; Xu L; Xu X
J BUON; 2021; 26(4):1355-1364. PubMed ID: 34564992
[TBL] [Abstract][Full Text] [Related]
5. Comparing the efficacy and safety of local-regional treatments for hepatocellular carcinoma with portal/hepatic vein tumor thrombosis in China: a network meta-analysis of randomized controlled trials.
Wu QQ; Gao H; Du SS; Chen YX; Hu Y; Yang P; Hou JZ; Zeng ZC
J BUON; 2021; 26(5):1950-1957. PubMed ID: 34761604
[TBL] [Abstract][Full Text] [Related]
6. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
[TBL] [Abstract][Full Text] [Related]
7. Comparison of different adjuvant therapy regimen efficacies in patients with high risk of recurrence after radical resection of hepatocellular carcinoma.
Feng X; Feng GY; Tao J; Ao YP; Wu XH; Qi SG; Shi ZR
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10505-10518. PubMed ID: 37284841
[TBL] [Abstract][Full Text] [Related]
8. Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma.
Guo JH; Liu SX; Gao S; Kou FX; Zhang X; Wu D; Li XT; Chen H; Wang XD; Liu P; Zhang PJ; Xu HF; Cao G; Zhu LZ; Yang RJ; Zhu X
World J Gastroenterol; 2020 Jul; 26(27):3975-3988. PubMed ID: 32774071
[TBL] [Abstract][Full Text] [Related]
9. Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis.
Feng F; Jiang Q; Jia H; Sun H; Chai Y; Li X; Rong G; Zhang Y; Li Z
Pharmacol Res; 2018 Sep; 135():89-101. PubMed ID: 29959032
[TBL] [Abstract][Full Text] [Related]
10. Which is the best combination of surgery for hepatocellular carcinoma with hepatic/portal vein thrombosis in China: a network meta-analysis of randomized controlled trials.
Wu QQ; Chen YX; Zheng TT; Dai MT; Ye T; Xu YH; Hu Y; Du SS; Zeng ZC
J BUON; 2021; 26(3):889-896. PubMed ID: 34268950
[TBL] [Abstract][Full Text] [Related]
11. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
Kodama K; Kawaoka T; Aikata H; Uchikawa S; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
J Gastroenterol Hepatol; 2018 Oct; 33(10):1780-1786. PubMed ID: 29645345
[TBL] [Abstract][Full Text] [Related]
12. Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis.
Qi X; Liu L; Wang D; Li H; Su C; Guo X
Oncotarget; 2015 Nov; 6(34):36838-59. PubMed ID: 26451613
[TBL] [Abstract][Full Text] [Related]
13. Transarterial chemoembolization plus iodine-125 implantation for hepatocellular carcinoma: a systematic review and meta-analysis.
Zhu ZX; Wang XX; Yuan KF; Huang JW; Zeng Y
HPB (Oxford); 2018 Sep; 20(9):795-802. PubMed ID: 29779970
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of interventional therapeutic modalities for unresectable hepatocellular carcinoma: A systematic review and network meta-analysis.
Chen XL; Yu HC; Fan QG; Yuan Q; Jiang WK; Rui SZ; Zhou WC
Oncol Lett; 2022 Oct; 24(4):366. PubMed ID: 36238837
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib in combination with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis.
Hu MD; Jia LH; Liu HB; Zhang KH; Guo GH
Eur Rev Med Pharmacol Sci; 2016; 20(1):64-74. PubMed ID: 26813455
[TBL] [Abstract][Full Text] [Related]
16. Transarterial chemoembolization combination therapy vs monotherapy in unresectable hepatocellular carcinoma: a meta-analysis.
Li L; Tian J; Liu P; Wang X; Zhu Z
Tumori; 2016 Jun; 2016(3):301-10. PubMed ID: 27002950
[TBL] [Abstract][Full Text] [Related]
17. Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
Huo YR; Eslick GD
JAMA Oncol; 2015 Sep; 1(6):756-65. PubMed ID: 26182200
[TBL] [Abstract][Full Text] [Related]
18. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of transarterial therapy combined with first-line tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a network meta-analysis.
Hu L; Lin J; Shi X; Wang A
World J Surg Oncol; 2023 Jul; 21(1):208. PubMed ID: 37475030
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index.
Ohki T; Kondo M; Karasawa Y; Kawamura S; Maeshima S; Kojima K; Seki M; Toda N; Shioda Y; Tagawa K
Adv Ther; 2017 May; 34(5):1097-1108. PubMed ID: 28389996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
